About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

The Company’s current product pipeline includes:

Talicia® (RHB-105) - An oral combination therapy for Helicobacter pylori infection with a U.S. NDA submitted and accepted by the FDA for priority review.

RHB-104 - An oral combination therapy with positive top-line results from a first Phase 3 study for Crohn's disease.

RHB-204 - An oral combination therapy with a planned pivotal Phase 3 study for nontuberculous mycobacteria (NTM) infections.

Bekinda® (RHB-102) - A once-daily oral pill formulation of ondansetron with positive results from a Phase 3 study in acute gastroenteritis and gastritis and positive results from a Phase 2 study in IBS-D.

Yeliva® (ABC294640) - an orally-administered, first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd. (now Bausch Health).

RHB-107  - A Phase 2-stage, orally-administered, first-in-class, serine protease inhibitor, targeting gastrointestinal and other solid tumor cancers. 

RedHill commercializes and promotes three gastrointestinal products in the U.S.:

Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis.

EnteraGam® - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Mytesi® - a prescription oral anti-diarrheal drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).